ArticleEpidemiology and psychiatric sciences2021
Use of antipsychotics in Denmark 1997-2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses.
Article in Epidemiology and psychiatric sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Efficacy and Acceptability of Licensed and Off-Label Pharmacological Interventions for Insomnia in Patients With Severe Mental Illness: A Systematic Review and Meta-Analysis of Randomised Trials.Acta psychiatrica Scandinavica · 2025Pooled it
- Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Incident mental disorders following cancer: analysis of real-world psychiatric outcomes in a nationwide population-based cohort study in Denmark across three decades.British journal of cancer · 2026Article
- From blood to brain: postmortem brain concentrations and brain-blood ratios of chlorprothixene, clozapine, olanzapine, and quetiapine.Journal of analytical toxicology · 2026Article
- Twenty-Year Trends in Antipsychotic Utilization in Serbia: A Nationwide Drug Utilization Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cardiovascular risk management in patients using antipsychotics: a qualitative feasibility study.BJGP open · 2026Article
- Trends in antipsychotic and lithium use in Scandinavian countries from 2010 to 2023: a cross-country drug utilization study.BMC psychiatry · 2026Article
- Antipsychotic off-label use in the 21st century: An enduring public health concern.Dialogues in clinical neuroscience · 2025Review
- Prescribing and deprescribing of atypical antipsychotics in older multimorbid patients.BMC geriatrics · 2025Article
- Clinical practice guidelines for the treatment of tardive dyskinesia in Europe: A descriptive review.European psychiatry : the journal of the Association of European Psychiatrists · 2025Review
- Transmural collaborative care model for cardiovascular risk management and medication review in patients using antipsychotics in primary care (TACTIC): A study protocol of an incomplete stepped wedge cluster randomized trial.Contemporary clinical trials communications · 2025Article
- FDA-approved drugs containing dimethylamine pharmacophore: a review of the last 50 years.RSC advances · 2024Review
- Healthcare professionals' experiences with the use of antipsychotics in dementia.Exploratory research in clinical and social pharmacy · 2024Article
- Transmural collaborative care model for the review of antipsychotics: a feasibility study of a complex intervention.Scientific reports · 2024Article
- Outpatient Antipsychotic Use and Severe COVID-19: Avoiding the Impact of Age in a Real-World Data Study.The international journal of neuropsychopharmacology · 2024Article
- On- and off-label utilisation of antipsychotics in Australia (2000-2021): Retrospective analysis of two medication datasets.The Australian and New Zealand journal of psychiatry · 2024Article
- Antipsychotic use during pregnancy and risk of specific neurodevelopmental disorders and learning difficulties in children: a multinational cohort study.EClinicalMedicine · 2024Article
- Distribution of quetiapine between serum and whole blood in therapeutic drug-monitoring specimens.Journal of analytical toxicology · 2024Article
- Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism.Frontiers in pharmacology · 2024Article
- Sedative drug-use in Denmark, 2000 to 2019: a nationwide drug utilization study.Social psychiatry and psychiatric epidemiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAntipsychotics are primarily labelled for the treatment of severe mental illness and have documented clinical utility in certain neurological disorders or palliative care. However, off-label use of antipsychotics is common and increasing, and prior studies on antipsychotic utilisation have not specifically assessed users in neurology, palliative care or general practice. We aimed to explore diagnoses associated with antipsychotic use, treatment patterns and characteristics of users without diagnoses relevant to antipsychotic treatment.
methodsPopulation-based study identifiying all users of antipsychotics in Denmark (pop 5.7 mio.) 1997-2018 in the Danish National Prescription Register (DNPR). Possible indications for antipsychotic therapy were evaluated using in- and outpatient contacts from the DNPR. Users were divided hierarchically into six groups: severe mental disorders (schizophrenia, bipolar-spectrum disorders), chronic mental disorders (dementias, mental retardation, autism), other mental disorders (depression-spectrum, anxiety and personality disorders, etc.), selected neurological diseases, cancer and antipsychotic users without any of these diagnoses. This last group was characterised regarding demographics, antipsychotic use, health care utilisation and likely antipsychotic treatment initiator in 2018.
resultsAltogether, 630 307 antipsychotic users were identified, of whom 127 649 had filled prescriptions during 2018. Users without diagnoses relevant to antipsychotic treatment comprised of the largest group (37%), followed by schizophrenia and bipolar-spectrum disorders (34%), other mental disorders (15%), dementia, autism and mental retardation (11%), cancer (2.2%) and neurological diagnoses (2.0%). Of 37 478 incident users in 2018, 39% had no diagnosis relevant to antipsychotic treatment, 7.9% had major depression, 7.7% neurotic/stress-related disorders and 7.5% dementia. Quetiapine was most commonly used, both overall (51%) and among users without diagnoses relevant to antipsychotic treatment (58%). Of 14 474 incident users in 2018 without diagnoses relevant to antipsychotic treatment, treatment was most likely initiated by a general practitioner (65%), with only 17% seeing a psychiatrist during the following year. As many as 18% of patients with adjustment disorders and 14% of those without relevant diagnoses for antipsychotic use, remained on antipsychotic treatment 5 years after their first prescription.
conclusionsOver one-third of antipsychotic users in Denmark did not have psychiatric, neurological or cancer diagnoses as possible indications for antipsychotic therapy. Many antipsychotics are initiated or prescribed in general practice, and a concerningly large subgroup without documented diagnoses relevant for antipsychotics continued to receive them. Rational prescribing, adequate side effect monitoring and further research into reasons for the observed antipsychotic use patterns and their risk-benefit ratio are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.